Justia Patents Opinion Summaries

Dental Monitoring SAS owns a patent concerning a method for acquiring and analyzing dental arch images through the use of a deep learning device. The patented method involves acquiring an image, analyzing it with the deep learning device, determining a value for an image attribute, comparing that attribute with a setpoint, and sending feedback if a new image is needed. Align Technology, Inc. challenged the validity of claims 1–15 of this patent before the United States Patent and Trademark Office’s Patent Trial and Appeal Board (the Board), arguing that these claims were obvious in light of three prior art references, including a U.S. patent application (“Carrier”) that claimed priority to a provisional application filed before the effective date of Dental Monitoring’s patent.The Board reviewed whether Carrier qualified as prior art, a determination that depended on whether Carrier could rely on the filing date of its provisional application. The Board held that, under its own precedential decision in Penumbra Inc. v. RapidPulse, Inc., the requirement that a patent’s claim be supported by the provisional application’s written description did not apply under the America Invents Act (AIA) for prior art purposes. Instead, the Board found that Carrier qualified as prior art as of its provisional filing date because the provisional described the relevant subject matter and met certain procedural requirements. The Board then found all challenged claims unpatentable as obvious.On appeal, the United States Court of Appeals for the Federal Circuit vacated the Board’s decision. The court held that, under AIA § 102(d)(2) and § 119(e), a reference patent or application is entitled to the benefit of an earlier filing date for prior art purposes only if at least one of its published claims is supported by the provisional application’s written description as required by § 112(a). The court remanded the case for the Board to make the necessary factual findings under this legal standard. View "DENTAL MONITORING SAS v. ALIGN TECHNOLOGY, INC. " on Justia Law

Socket Solutions, LLC owns a patent covering an indoor electrical wall outlet cover that allows continued use of the outlet while concealing the outlet’s contact openings. The company alleged that Import Global, LLC’s Neat Socket product infringed claim 19 of this patent. Socket Solutions filed suit in the United States District Court for the Southern District of Florida and sought a preliminary injunction to prevent Import Global from manufacturing, using, selling, or importing the accused product in the United States.A magistrate judge in the district court issued reports and recommendations regarding both claim construction and the preliminary injunction motion. The district court adopted these recommendations, with minor modifications not relevant on appeal, and granted Socket Solutions the preliminary injunction. This order barred Import Global from engaging in activities related to the allegedly infringing product, as well as any products not more than colorably different from it, and from inducing others to do so.The United States Court of Appeals for the Federal Circuit reviewed the district court’s grant of the preliminary injunction. The appellate court found that the district court erred in its construction of the patent claim terms “backplate” and “pin” during its analysis of the likelihood of success on the merits. The Federal Circuit held that “backplate” should be construed as the component forming the cover with the frontplate, such that the maximum thickness of the cover is the distance, at the central portion of the cover, between the frontplate and that component, and that “pin” should be given its plain and ordinary meaning as understood by a skilled artisan. The Federal Circuit vacated the preliminary injunction and remanded the case for further proceedings consistent with its opinion. Costs were awarded to Import Global. View "SOCKET SOLUTIONS, LLC v. IMPORT GLOBAL, LLC " on Justia Law

The dispute involved a university and its licensee, who hold a patent describing a biodegradable polymer fiber containing a therapeutic agent, which can be used in medical implants such as drug-eluting stents. The patent claims compositions where the fiber is composed of two immiscible phases: a polymer portion and discrete regions containing the drug. The defendant, a medical device company, manufactured and sold stents with a drug-containing biodegradable coating, which the plaintiffs alleged infringed several claims of the patent.After the lawsuit was transferred to the United States District Court for the District of Delaware, the court construed key claim terms and the case proceeded to a jury trial. The jury found that the defendant infringed the asserted patent claims and did so willfully, rejected the defendant’s invalidity defense based on anticipation by a prior patent (the “Song” reference), and awarded damages. The district court later set aside the willfulness finding but otherwise upheld the verdict and entered judgment for the plaintiffs.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the district court’s denial of the defendant’s motions for judgment as a matter of law de novo. The appellate court concluded that the Song patent anticipated all asserted claims, finding that it expressly disclosed every limitation at issue, including the specific structure of the fiber, drug-containing regions, and release characteristics. The court also determined that no reasonable jury could have found infringement, as the defendant’s stent coating did not meet the “fiber” limitation under the district court’s construction. Accordingly, the Federal Circuit reversed the judgment for the plaintiffs and did not reach the plaintiffs’ cross-appeal regarding willfulness. The court awarded costs to the defendant. View "BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS v. BOSTON SCIENTIFIC CORP. " on Justia Law

This case concerns a dispute over the alleged infringement of a patent related to an insulated overhead door. Cold Chain, LLC owns U.S. Patent No. 9,151,084, and Ridge Corporation became its exclusive licensee in February 2023. Ridge alleged that Kirk NationaLease Co., Truck & Trailer Parts Solutions, Inc., and Altum LLC infringed claims of the patent by manufacturing and selling a roll-up door. Ridge also brought claims for patent inducement, contributory infringement, tortious interference with business relationships, and false patent marking. The accused product is constructed as a “sandwich” panel with two thermoplastic membranes surrounding a foam layer, which is modified to traverse curved tracks.The United States District Court for the Southern District of Ohio initially granted Ridge’s motion for a preliminary injunction, enjoining the defendants from certain activities related to the accused door. The United States Court of Appeals for the Federal Circuit vacated that injunction, finding Ridge lacked standing as it was not an exclusive licensee with all substantial rights. Ridge then amended its complaint, adding Cold Chain as a plaintiff, and the district court again granted a preliminary injunction, concluding the plaintiffs had a strong likelihood of success on the merits.Upon review, the United States Court of Appeals for the Federal Circuit reversed the district court’s order. The court held that the defendants raised substantial questions regarding whether the accused door met three distinct claim limitations: flexibility along the entire length, the foam forming the second outermost surface, and whether the door qualifies as an “insulated overhead door.” The court also found the plaintiffs failed to demonstrate irreparable harm. The preliminary injunction was therefore reversed and the case remanded for further proceedings. View "RIDGE CORP. v. KIRK NATIONALEASE CO. " on Justia Law

The matter concerns a patent covering methods for generating digital images using an external visual server, offloading intensive image processing from a client device to a server that generates, compresses, and transmits images back to the client for display. The patent’s claimed improvement over prior art is the complete transfer of visual processing to the external server, so that the client only handles user input and image decompression. Sony sought inter partes review of twelve claims in the patent, arguing they were obvious in light of prior art, particularly a patent (“Wiltshire”) that described a server-based gaming system transmitting compressed images to clients.Previously, the Patent Trial and Appeal Board (the Board) initially found the claims not unpatentable, concluding Wiltshire did not disclose “generating” images at the server as required by the claims. On Sony’s appeal, the United States Court of Appeals for the Federal Circuit vacated that decision, holding that Wiltshire did disclose generating new images at the server, especially since it referenced games such as Doom that require real-time image generation. The Federal Circuit remanded for further proceedings. On remand, the Board found that Wiltshire, in combination with another reference (“Saha”) disclosing MPEG compression, taught all claim limitations, including the necessary image compression and transmission steps, and held all challenged claims unpatentable as obvious.On appeal, the United States Court of Appeals for the Federal Circuit reviewed whether the Board had exceeded the scope of its mandate or lacked substantial evidence for its findings. The Federal Circuit held that the Board properly followed its mandate, did not improperly revisit issues, and that substantial evidence supported the Board’s finding that the prior art disclosed all elements of the challenged claims. The court affirmed the Board’s decision, holding the claims unpatentable as obvious. View "INTELLECTUAL PIXELS LIMITED v. SONY INTERACTIVE ENTERTAINMENT LLC " on Justia Law

The dispute centered on two patents owned by Wyeth that claim methods of treating non-small cell lung cancer (NSCLC) resistant to two specific drugs, gefitinib and erlotinib, by administering “irreversible” EGFR inhibitors. The patents require the daily administration of a “unit dosage” of an irreversible EGFR inhibitor that covalently binds to specific amino acids in the EGFR protein. The patent specifications list three example compounds, describe in vitro test results, and provide general dosage ranges. However, the specifications do not include any working examples of dosing regimens administered to human patients, nor do they explain how to reliably determine a therapeutically effective and safe dosage for such patients.In the United States District Court for the District of Delaware, Wyeth sued AstraZeneca for alleged infringement based on AstraZeneca’s marketing of an irreversible EGFR inhibitor. After a jury found in Wyeth’s favor, determining the asserted patent claims were not invalid and awarding damages, AstraZeneca renewed its motion for judgment as a matter of law (JMOL), arguing that the patents were invalid for lack of enablement. The district court granted JMOL, concluding that the patents did not provide sufficient guidance for a skilled artisan to determine a suitable daily unit dosage for patients without undue experimentation, especially given the evidence that some disclosed dosage ranges would be toxic in humans.The United States Court of Appeals for the Federal Circuit affirmed the district court’s judgment. The Federal Circuit held that the asserted claims were invalid for lack of enablement under 35 U.S.C. § 112(a). The court concluded that the patent specifications failed to teach skilled artisans how to determine, without undue experimentation, daily unit dosages that would be therapeutically effective and safe for patients across the full scope of the claimed compounds. View "WYETH LLC v. ASTRAZENECA PHARMACEUTICALS LP " on Justia Law

TrackTime, LLC owned two patents claiming methods and systems for navigating within multimedia files on a mobile device using a time-correlated transcript. The patents described creating a synchronization index that allows users to tap on text to play corresponding multimedia segments and to annotate and share transcripts. TrackTime sued Amazon.com Services LLC and Audible, Inc. for patent infringement in the United States District Court for the District of Delaware, asserting claims from both patents.In the District of Delaware, the court ruled on two sets of claims. For the ’978 patent, the court construed certain limitations as means-plus-function terms under 35 U.S.C. § 112(f) and found the claims indefinite due to insufficient structural disclosure in the specification, leading to a holding of invalidity. For the ’638 patent, a jury trial was held focusing on claim 9. The jury found claim 9 not infringed and invalid for anticipation, as well as for other grounds. TrackTime’s post-trial motions for judgment as a matter of law and for a new trial were denied. Final judgment was entered accordingly.The United States Court of Appeals for the Federal Circuit reviewed the case. For the ’978 patent, the court found that further analysis was needed regarding whether the “executable program code” limitations should be considered means-plus-function terms under § 112(f), especially in light of intervening precedent from Dyfan, LLC v. Target Corp. The court vacated the district court’s indefiniteness ruling and remanded for further proceedings. For the ’638 patent, the Federal Circuit affirmed the judgment of invalidity for anticipation, holding there was sufficient evidence for the jury to find claim 9 anticipated by LiveNote and affirming the denial of post-trial motions. The disposition was affirmed in part, vacated in part, and remanded. View "TRACKTIME, LLC v. AMAZON.COM SERVICES LLC " on Justia Law

Otsuka America Pharmaceutical and its subsidiary own a patent covering a method for treating pseudobulbar affect and emotional lability by administering dextromethorphan with quinidine. Their branded drug, Nuedexta, combines these substances in their salt forms. After the FDA approved Hetero Labs’ generic version, which uses identical salt forms and amounts, Hetero announced plans to launch its product. Otsuka responded by filing suit in the United States District Court for the District of Delaware, seeking a temporary restraining order and a preliminary injunction to block Hetero’s market entry.The District Court for the District of Delaware first issued a temporary restraining order, then granted a preliminary injunction, preventing Hetero from selling its generic drug. The court found Otsuka likely to succeed in proving patent infringement and determined that equitable factors favored the injunction. It also waived the requirement for Otsuka to post a bond pending appeal, citing strong equities in Otsuka’s favor.The United States Court of Appeals for the Federal Circuit reviewed the case. It affirmed the district court’s interpretation of the patent claim terms “dextromethorphan” and “quinidine” as including both the free base and salt forms administered to patients, rather than only the active moiety. This construction meant that Hetero’s generic product infringed the patent. The Federal Circuit also held that the district court acted within its discretion in granting the preliminary injunction. However, it vacated the district court’s waiver of the Rule 65(c) bond requirement, finding that such waivers are extremely rare in cases involving commercial activity, and remanded the issue for reconsideration. Thus, the preliminary injunction was affirmed but the bond waiver was vacated and remanded. View "OTSUKA AMERICA PHARMACEUTICAL, INC. v. HETERO LABS LIMITED " on Justia Law

Norwich Pharmaceuticals sought to market a generic version of Xifaxan, a drug invented by Salix Pharmaceuticals for treating irritable bowel syndrome with diarrhea and hepatic encephalopathy. Norwich submitted an Abbreviated New Drug Application (ANDA) to the FDA, identified as number 214369. Salix believed this ANDA infringed its patents and sued Norwich in the United States District Court for the District of Delaware. That court found Norwich’s ANDA infringed Salix’s patents related to hepatic encephalopathy, while the patents for irritable bowel syndrome were invalid as obvious. The court’s final judgment barred FDA approval of Norwich’s ’369 ANDA until Salix’s hepatic encephalopathy patents expired in October 2029.Following the judgment, Norwich amended its ’369 ANDA to remove the indication for hepatic encephalopathy and requested the Delaware District Court modify its judgment to allow immediate FDA approval of the amended ANDA. The court denied this motion, reasoning that Norwich could not change its ANDA after final judgment to circumvent the prior ruling. Norwich appealed to the United States Court of Appeals for the Federal Circuit, which agreed the judgment restricted approval of the entire ANDA, including non-infringing indications, until 2029, and affirmed the Delaware District Court’s decision.After the FDA declined to grant final approval of Norwich’s amended ANDA, instead issuing only tentative approval, Norwich sued in the United States District Court for the District of Columbia, arguing the FDA acted arbitrarily and capriciously. The court granted summary judgment to the FDA and Salix. On appeal, the United States Court of Appeals for the District of Columbia Circuit held that the Delaware District Court’s judgment applied to Norwich’s ANDA as amended, so the FDA correctly delayed final approval until October 2029. The appellate court affirmed the district court’s judgment. View "Norwich Pharmaceuticals, Inc. v. Kennedy" on Justia Law

Enanta Pharmaceuticals owned a patent directed to certain chemical compounds and methods for inhibiting coronavirus replication. The patent claimed priority to an earlier provisional application filed in July 2020. In the original provisional application, the relevant chemical group was described as containing two to twelve carbon atoms, while in the later patent, the range was changed to include one to twelve carbon atoms. Before the non-provisional patent was filed, Pfizer publicly disclosed a compound that fell within the scope of Enanta’s later patent claims.Enanta filed suit in the United States District Court for the District of Massachusetts, asserting that Pfizer’s product infringed its patent. Pfizer countered that the patent was invalid because its public disclosure anticipated the patent claims, and argued that Enanta’s patent could not claim priority to the earlier provisional application since the specific chemical group was not adequately supported in the provisional filing. The district court granted summary judgment in Pfizer’s favor, concluding that the change from two to one carbon atoms was not a correctable typographical error, and that the patent could not claim the earlier priority date.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the district court’s decision de novo. The appellate court held that the provisional application did not provide written description support for the later patent’s claims, specifically the inclusion of the one-carbon group, and thus the patent was not entitled to the earlier priority date. As a result, Pfizer’s disclosure anticipated all claims of Enanta’s patent, rendering them invalid. The Federal Circuit affirmed the district court’s grant of summary judgment. View "ENANTA PHARMACEUTICALS, INC. v. PFIZER INC. " on Justia Law